D
Avidity Biosciences, Inc.
RNA
$26.57
-$1.53-5.45%
D
Sell
1/19/2024Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 1/19/2024 due to an increase in the total return index, solvency index and volatility index.
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 1/19/2024 due to an increase in the total return index, solvency index and volatility index.
E
Sell
1/4/2024Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
D
Sell
12/13/2023Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 12/13/2023 due to an increase in the solvency index, volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 12/13/2023 due to an increase in the solvency index, volatility index and total return index.
E
Sell
11/28/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 11/28/2023 due to a decline in the solvency index, volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 11/28/2023 due to a decline in the solvency index, volatility index and total return index.
D
Sell
11/10/2023Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index.
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index.
E
Sell
11/1/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 11/1/2023 due to a decline in the volatility index and growth index.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 11/1/2023 due to a decline in the volatility index and growth index.
D
Sell
10/17/2023Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 10/17/2023 due to an increase in the volatility index.
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 10/17/2023 due to an increase in the volatility index.
E
Sell
10/2/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 10/2/2023 due to a decline in the volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 10/2/2023 due to a decline in the volatility index and total return index.
D
Sell
9/15/2023Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 9/15/2023 due to an increase in the volatility index and valuation index.
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 9/15/2023 due to an increase in the volatility index and valuation index.
E
Sell
8/29/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index and total return index.
D
Sell
8/14/2023Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 8/14/2023 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.7439 to -$0.6587, EBIT increased 8.62% from -$57.6M to -$52.63M, and the quick ratio increased from 12.21 to 12.77.
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 8/14/2023 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.7439 to -$0.6587, EBIT increased 8.62% from -$57.6M to -$52.63M, and the quick ratio increased from 12.21 to 12.77.
E
Sell
8/1/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 8/1/2023 due to a decline in the volatility index, growth index and total return index.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 8/1/2023 due to a decline in the volatility index, growth index and total return index.
D
Sell
7/17/2023Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 7/17/2023 due to an increase in the volatility index.
Avidity Biosciences, Inc. (RNA) was upgraded to D- from E+ on 7/17/2023 due to an increase in the volatility index.
E
Sell
6/29/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 6/29/2023 due to a large decline in the total return index, volatility index and solvency index.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D- on 6/29/2023 due to a large decline in the total return index, volatility index and solvency index.
D
Sell
3/14/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index. Operating cash flow declined 22.62% from -$31.96M to -$39.19M, EBIT declined 18.46% from -$44.93M to -$53.23M, and earnings per share declined from -$0.8216 to -$0.8809.
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index. Operating cash flow declined 22.62% from -$31.96M to -$39.19M, EBIT declined 18.46% from -$44.93M to -$53.23M, and earnings per share declined from -$0.8216 to -$0.8809.
D
Sell
2/23/2023Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 11.85 to 9.54.
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 11.85 to 9.54.
D
Sell
8/25/2022Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 8/25/2022 due to an increase in the total return index and volatility index.
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 8/25/2022 due to an increase in the total return index and volatility index.
D
Sell
8/10/2022Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 8/10/2022 due to a noticeable decline in the growth index and volatility index. EBIT declined 34.36% from -$34.46M to -$46.3M, earnings per share declined from -$0.7096 to -$0.92, and operating cash flow declined 20.19% from -$29.57M to -$35.55M.
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 8/10/2022 due to a noticeable decline in the growth index and volatility index. EBIT declined 34.36% from -$34.46M to -$46.3M, earnings per share declined from -$0.7096 to -$0.92, and operating cash flow declined 20.19% from -$29.57M to -$35.55M.
D
Sell
5/31/2022Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
D
Sell
5/13/2022Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/5/2022Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Avidity Biosciences, Inc. (RNA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
Avidity Biosciences, Inc. (RNA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
D
Sell
11/9/2021Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index and total return index.
E
Sell
11/8/2021Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D on 11/8/2021 due to a substantial decline in the efficiency index, solvency index and total return index. Net income declined 10.52% from -$23.84M to -$26.35M, total capital declined 7.55% from $287.07M to $265.39M, and the quick ratio declined from 17.65 to 17.19.
Avidity Biosciences, Inc. (RNA) was downgraded to E+ from D on 11/8/2021 due to a substantial decline in the efficiency index, solvency index and total return index. Net income declined 10.52% from -$23.84M to -$26.35M, total capital declined 7.55% from $287.07M to $265.39M, and the quick ratio declined from 17.65 to 17.19.
D
Sell
2/3/2021Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to D from D+ on 2/3/2021 due to a large decline in the volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was downgraded to D from D+ on 2/3/2021 due to a large decline in the volatility index and total return index.
D
Sell
1/19/2021Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D+ from D on 1/19/2021 due to an increase in the volatility index and valuation index.
Avidity Biosciences, Inc. (RNA) was upgraded to D+ from D on 1/19/2021 due to an increase in the volatility index and valuation index.
D
Sell
1/4/2021Downgrade
Avidity Biosciences, Inc. (RNA) was downgraded to D from D+ on 1/4/2021 due to a noticeable decline in the volatility index, efficiency index and valuation index. Net income declined 8.36% from -$10.56M to -$11.44M, and total capital declined 3.06% from $330.98M to $320.85M.
Avidity Biosciences, Inc. (RNA) was downgraded to D from D+ on 1/4/2021 due to a noticeable decline in the volatility index, efficiency index and valuation index. Net income declined 8.36% from -$10.56M to -$11.44M, and total capital declined 3.06% from $330.98M to $320.85M.
D
Sell
9/8/2020Upgraded
Avidity Biosciences, Inc. (RNA) was upgraded to D+ from D on 9/8/2020 due to an increase in the volatility index and total return index.
Avidity Biosciences, Inc. (RNA) was upgraded to D+ from D on 9/8/2020 due to an increase in the volatility index and total return index.
D
Sell
9/4/2020None
Avidity Biosciences, Inc. (RNA) was downgraded to D from U on 09/04/2020.
Avidity Biosciences, Inc. (RNA) was downgraded to D from U on 09/04/2020.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
